New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:17 EDTHZNPHorizon Pharma price target raised to $25 from $18 at Stifel
Stifel increased its price target on Horizon as the firm thinks that the company's acquisition of Vidara has left it in "ideal position" to become profitable and meet its revenue and EBITDA guidance. The firm thinks the company's drug portfolio is poised to perform well, and keeps a Buy rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information
October 13, 2014
17:06 EDTHZNPHorizon Pharma: Actimmune net sales potential $500M with FDA approval for FA
Subscribe for More Information
05:31 EDTHZNPHorizon Pharma to host analyst day
Analyst Day to be held in King of Prussia, PA on October 13 at 5 pm. Webcast Link
October 9, 2014
15:31 EDTHZNPHorizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale
Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.
13:40 EDTHZNPHorizon Pharma presents ACTIMMUNE Phase 2 data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use